To investigate the expressions of ZFP36L1 in MIBCs of different molecular biological characteristics, we compared the expression levels of ZFP36L1 in the 6 subtypes of TCGA-BLCA patients (p = 5.5e-07, Kruskal–Wallis test) (Figure 2F; Supplementary Table S1). This evidence concerns the gene ZFP36L1 and bladder transitional cell carcinoma.